
The FDA continues to endorse the adoption of LED and near-infrared photobiomodulation therapies, asserting their safety and efficacy for various medical applications while initiating focused research to address critical knowledge gaps. Notable areas of study include high-intensity treatment safety thresholds, retinal exposure hazards, and their effects on fat cell dynamics, ensuring continued confidence in non-invasive therapy despite unanswered questions. This strategic position underlines the growing role of LED devices in chronic pain management and skin health, particularly as demand for effective home-use treatments rises.
“Dr. Apple Bodemer is a board-certified dermatologist and professor of dermatology at the University of Wisconsin School of Medicine and Public Health.”